The Rare Case Where the Confidence
Was Actually Earned

Creatine's longevity claims hold up under real scrutiny — a useful example of genuine evidence versus marketing.

Filed by: Neal Lloyd · Clearance: Public · 8 Min Read

Most confident claims about health and performance don't survive close scrutiny. It's worth noticing, then, the rare case where a claim actually does — because recognizing the difference is a skill, not a coincidence.

Creatine has three decades of research behind it, including a real FDA safety classification and, more recently, studies specifically on aging populations rather than just athletes chasing gym performance. That's a meaningfully different evidence bar than most trending supplements clear, and it's worth understanding exactly why this one earned its confidence while so many others haven't.

This is also a useful template for evaluating any confident claim, in health or otherwise: look for research on the actual population making the claim, real safety data at real doses, and independent replication. Here's what that looks like applied to creatine specifically.

The Actual Research, Not the Marketing Copy

Creatine has existed as a mainstream sports supplement since the 1990s, primarily associated with bodybuilders and strength athletes chasing marginal gains in the gym. What's changed dramatically over the past two years is the research population: scientists have started studying creatine specifically in aging populations, tracking outcomes that have nothing to do with how much weight someone can bench press.

A 2025 study found that natural creatine synthesis and dietary intake both decline progressively with age — and, more specifically, that this decline appears connected to changes in DNA methylation patterns that independently predict biological aging and mortality risk. That's a genuinely different category of finding than "helps you lift more." DNA methylation is one of the more rigorously studied biomarkers in aging research precisely because it correlates with real-world health outcomes rather than subjective feelings of vitality — the kind of marker researchers take seriously specifically because it's hard to fake or spin.

Skepticism that never finds anything worth actually endorsing isn't rigor. It's just a different flavor of bias, wearing a lab coat instead of a gym selfie.

On muscle specifically, the research is even more directly applicable to anyone over 40 paying attention to healthy aging: when combined with resistance training, creatine supplementation helped older adults gain roughly three pounds more lean muscle than resistance training alone. That matters enormously in the context of sarcopenia — the age-related muscle loss that's one of the most significant, well-documented drivers of declining mobility, independence, and fall risk in older adults. This isn't a cosmetic gym-bro outcome. Preserved muscle mass in your 60s and 70s is directly, causally connected to whether you can still get up off the floor unassisted, whether a fall becomes a minor incident or a hip fracture, and how long you maintain functional independence.

The cognitive research is newer and slightly less conclusive, but pointing in a consistent direction. Brain creatine levels can increase by roughly 11% with supplementation, and systematic reviews link that increase to measurable improvements in memory and attention — with the effect appearing most pronounced specifically in people who started with lower baseline creatine levels, which notably includes older adults and vegetarians, two populations with genuinely elevated risk of creatine insufficiency from diet alone.

Why This One Survived Where So Many Others Didn't

Here's the actual mechanism worth understanding, because it's not really about creatine being a magic molecule. It's about creatine being one of the most thoroughly studied compounds in all of sports nutrition, at doses and durations that most trendier longevity supplements have never come close to matching.

The FDA classified creatine as Generally Recognized as Safe back in 2020 — a real regulatory designation, not a marketing claim. Safety research specifically examined high doses over extended periods: no kidney damage was observed in healthy individuals taking 20 grams daily for 24 continuous months, a study duration and dosage far beyond what almost any newer "longevity compound" has been tested at before hitting the consumer market. The commonly cited concern about elevated blood creatinine levels turns out to be a benign metabolic byproduct of creatine metabolism itself, not evidence of kidney dysfunction — a distinction that took years of dedicated research to establish clearly, and one that most fear-based supplement marketing conveniently never bothers to explain to consumers.

Compare that evidentiary base to something like NMN, currently being promoted heavily as 2026's breakout longevity trend for its role in supporting NAD+ levels. The theoretical mechanism is genuinely interesting and worth continued research attention — but the human clinical evidence remains meaningfully thinner than what exists for creatine, precisely because NMN hasn't had three decades of dedicated athletic and clinical research establishing both its safety profile and its actual effects at the doses being sold to consumers today. That's not a dismissal of NMN's future potential. It's a statement about which supplement currently has the stronger evidentiary claim to the word "proven," and creatine wins that specific comparison clearly and by a wide margin.

The Part the Supplement Industry Still Manages to Ruin

Even with creatine's genuinely strong evidence base, the supplement industry has found ways to layer unnecessary complexity and cost on top of a compound that's fundamentally simple and cheap.

Creatine monohydrate — the plain, original, extensively studied form — remains, according to the actual research literature, the gold standard. It is also, not coincidentally, the cheapest form available, typically costing just a few cents per daily dose. Newer variants like micronized creatine claim improved solubility, which is true but provides no additional performance or health benefit over standard monohydrate — you're paying a premium purely for a marginally less gritty texture in your water. Creatine HCl claims better absorption at lower doses, but has meaningfully less research support than monohydrate, meaning you're trading a well-established compound for a less-studied one, based on manufacturer claims rather than independent verification. No alternative form has demonstrated actual superiority over monohydrate in properly controlled studies, which makes the entire premium-creatine category functionally a tax on people who assume "newer and more expensive" automatically means "better" — the exact same assumption the testosterone industry weaponizes far more aggressively and far less honestly.

There's also a newer wave of "3-in-1" longevity-branded creatine products — pairing plain creatine monohydrate with additional ingredients like HMB and pomegranate-derived urolithin A precursors, marketed explicitly toward an aging, longevity-conscious demographic willing to pay considerably more per dose for a compound formulation. Some of those additional ingredients have genuine, if less extensively studied, supporting research of their own. But the honest framing here matters: you're paying a substantial premium for a bundled product built around a genuinely excellent, extremely cheap core ingredient, and it's worth knowing that distinction clearly before deciding whether the added ingredients are worth the markup for your specific situation, rather than assuming the premium packaging itself signals additional efficacy.

What This Actually Teaches About Reading Supplement Claims

The useful skill here isn't "take creatine, skip everything else" — plenty of other supplements have real, if less extensively documented, evidence behind them too. The actually valuable skill is learning to distinguish the specific signals that separate a genuinely evidence-backed claim from a well-marketed one, because those signals are consistent and learnable across categories.

Look for research conducted specifically on the population making the claim — creatine's aging-focused research is recent and specific to older adults, not just extrapolated from decades-old bodybuilder studies. Look for safety data at the actual doses and durations being sold, not just short-term studies conveniently truncated before any downside might show up. Look for independent replication across multiple research groups rather than a single company-funded study driving all the marketing copy. And look, critically, for financial disclosure — whether the people making the claim have a direct financial stake in you believing it, the exact dynamic that made the testosterone influencer economy so structurally compromised, where the earlier UNNECESSARY analysis found that the overwhelming majority of "low T" content creators had undisclosed financial interests in the products they were recommending.

Creatine clears every one of these bars cleanly, which is precisely why it's worth naming as the exception rather than assuming this entire editorial series exists purely to tear down every supplement claim on principle. Skepticism that never finds anything worth actually endorsing isn't rigor. It's just a different flavor of bias, wearing a lab coat instead of a gym selfie.

The House of Kong Take

The Citadel doesn't distrust supplements. The Citadel distrusts unearned confidence. Creatine earned its confidence the hard way — three decades of research, a real FDA safety designation, and evidence that actually holds up in the specific population now buying it. That's the bar. Almost nothing else in this category clears it yet.

Coming Up — Issue 015

Jeff Bezos paid $500 million for a yacht. Spielberg paid $250 million for another. The smartest people in that exact tax bracket are increasingly deciding not to buy one at all.